Mammary Cell News 11.49 December 19, 2019 | |
| |
TOP STORYp27 Allosterically Activates Cyclin-Dependent Kinase 4 and Antagonizes Palbociclib Inhibition Palbociclib primarily targeted the cyclin D-dependent kinases CDK4 and CDK6 in breast cancer cells, and this association indirectly inhibited the downstream Rb-inactivating kinase CDK2. [Science] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Elevated Tribble 3 expression supported breast cancer stem cells by interacting with AKT to interfere with the FOXO1-AKT interaction and suppressed FOXO1 phosphorylation, ubiquitination, and degradation by E3 ligases SKP2 and NEDD4L. [Nat Commun] Full Article Scientists demonstrated that FOXA1 overexpression in ER+ breast cancer cells drove genome-wide enhancer reprogramming to activate prometastatic transcriptional programs. [Proc Natl Acad Sci USA] Abstract Investigators revealed that VASP was located in the nucleus of breast cancer cells and elucidated a Wnt/β-catenin/VASP positive feedback loop. They identified that VASP was a target gene of Wnt/β-catenin signaling pathway. [Oncogene] Abstract TLR5: A Prognostic and Monitoring Indicator for Triple-Negative Breast Cancer Researchers established triple-negative breast cancer cell line 4T1 with low toll-like receptor 5 (TLR5) expression and with normal TLR5 expression using lentivirus-shRNA-TLR5 knockdown transfection and negative lentivirus transfection, respectively. [Cell Death Dis] Full Article The effects of serotonin on human breast cancer cells proliferation, signaling pathways and metabolic profile were evaluated by cytometry, western blotting, qPCR, enzymology and confocal microscopy. [Br J Cancer] Abstract The authors report a novel mechanism of action of chemically modified, tryptone-stabilized gold nanoparticles in the triple-negative breast cancer cell line, MDA-MB-231. [Sci Rep] Full Article The modulation evaluation of leptin receptor expression in the presence of leptin and tamoxifen stimuli was performed in breast cancer cell lines as a model of initial approach for the study of breast cancer subtypes and their behavior to the action response of adipokines. [Sci Rep] Full Article MicroRNA-710 Regulates Multiple Pathways of Carcinogenesis in Murine Metastatic Breast Cancer Scientists introduced miR-710 mimics into 4T1 metastatic breast adenocarcinoma cells and assessed the resultant phenotypic effects. They demonstrated significant inhibition of cell viability, migration, and invasion. [PLoS One] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSMechanisms of Resistance to Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer Scientists conclude that the T-DM1 resistance mechanisms most strongly supported by the experimental data relate to dysfunctional intracellular metabolism of the construct and subversion of DM1-mediated cell killing. [Br J Cancer] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSSusan G. Komen® Study Confirms Treatment Options for HER2-Negative Patients with BRCA1/2 Mutations Susan G. Komen® welcomed the results of the INFORM trial that were announced at the 2019 San Antonio Breast Cancer Symposium. The Komen-funded INFORM trial led by Dr. Nadine Tung shows that HER2-negative patients with a BRCA1/2 gene mutation have multiple effective treatment options. [Susan G. Komen] Press Release New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues demonstrated a potential utility for monitoring tumor-specific mutations in the circulation of early stage triple-negative breast cancer patients. [Sysmex Inostics] Press Release Athenex, Inc. announced results from a pivotal Phase III clinical trial showed oral paclitaxel and encequidar had superior response and survival with much lower incidence and severity of neuropathy compared to IV paclitaxel in the treatment of metastatic breast cancer. [Athenex, Inc.] Press Release | |
| |
POLICY NEWSAnother year, another 1,433 (and counting) retractions. The tenth year of Retraction Watch’s existence included-as is often the case-a new record, some impressive numbers, and some bizarre stories. But it also included some exemplary behavior. [The Scientist] Editorial NIH Considering New Recommendations on Sexual Harassment Policies Recommendations put forth by the Working Group on Changing the Culture to End Sexual Harassment include requiring NIH-funded institutions to notify the agency within two weeks when a grant recipient is found guilty of sexual misconduct, barring confirmed harassers from serving on NIH advisory councils, and mandating that grant applicants report sexual harassment findings against them. [The Scientist] Editorial Success in science requires building top performing teams to push the boundaries of what is known—and this means attracting and nurturing scientific talent. In today’s political climate of possible scientific funding cuts and immigration policy uncertainty, headlines forecast a grim effect on scientific research. [Scientific American] Editorial
| |
EVENTSNEW Lorne Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Training Fellow – Breast Cancer Research (Institute of Cancer Research) Leader – Breast Cancer Program (Fred Hutchinson Cancer Research Center) Postdoctoral Training Fellow – Molecular Oncology (Institute of Cancer Research) Postdoctoral Position – Fibroblasts in Breast Cancer (Institut Curie) Postdoctoral Fellowship – Molecular Mechanisms in Cancers (Cleveland Clinic) Senior/Research Associate – In Vivo Pharmacology for Oncology Research (Moderna) Postdoctoral Fellow – Breast Cancer Stem Cells (Dalhousie University) Research Scholar – Breast Cancer (Eastern Virginia Medical School) Postdoctoral Scholar – Breast Cancer (The University of Kentucky) Postdoctoral Associate – Immune Responses (The Jackson Laboratory) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|